The global market for Viral Vector Manufacturing is estimated at US$807.1 Million in 2023 and is projected to reach US$2.6 Billion by 2030, growing at a CAGR of 18.3% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
The growth in the viral vector manufacturing market is driven by several factors. The increasing prevalence of genetic disorders and the expanding pipeline of gene therapies in clinical development have significantly boosted the demand for viral vectors. The success of gene therapies, such as Luxturna and Zolgensma, and the approval of CAR-T cell therapies have demonstrated the potential of viral vectors in treating previously intractable diseases, encouraging further investment and research in this field. The COVID-19 pandemic also underscored the importance of viral vectors in vaccine development, with several vaccines, including those developed by Johnson & Johnson and AstraZeneca, utilizing viral vector technology. Additionally, advancements in vector engineering and manufacturing technologies have enhanced the efficiency and scalability of production processes, making viral vector therapies more accessible and cost-effective. Regulatory support and funding from government agencies and private investors are further propelling market growth. The increasing collaborations and partnerships between biotech companies, academic institutions, and CMOs are expanding manufacturing capabilities and accelerating the development and commercialization of viral vector-based therapies. These factors collectively ensure the robust growth of the viral vector manufacturing market, fostering continuous innovation and wider adoption in various therapeutic applications.
The growth in the viral vector manufacturing market is driven by several factors. The increasing prevalence of genetic disorders and the expanding pipeline of gene therapies in clinical development have significantly boosted the demand for viral vectors. The success of gene therapies, such as Luxturna and Zolgensma, and the approval of CAR-T cell therapies have demonstrated the potential of viral vectors in treating previously intractable diseases, encouraging further investment and research in this field. The COVID-19 pandemic also underscored the importance of viral vectors in vaccine development, with several vaccines, including those developed by Johnson & Johnson and AstraZeneca, utilizing viral vector technology. Additionally, advancements in vector engineering and manufacturing technologies have enhanced the efficiency and scalability of production processes, making viral vector therapies more accessible and cost-effective. Regulatory support and funding from government agencies and private investors are further propelling market growth. The increasing collaborations and partnerships between biotech companies, academic institutions, and CMOs are expanding manufacturing capabilities and accelerating the development and commercialization of viral vector-based therapies. These factors collectively ensure the robust growth of the viral vector manufacturing market, fostering continuous innovation and wider adoption in various therapeutic applications.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Retroviral Vectors segment, which is expected to reach US$954.6 Million by 2030 with a CAGR of a 18.1%. The Adenoviral Vectors segment is also set to grow at 18.5% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $477.0 Million in 2023, and China, forecasted to grow at an impressive 21.4% CAGR to reach $107.9 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Viral Vector Manufacturing Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Viral Vector Manufacturing Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Viral Vector Manufacturing Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as Bayer AG, Janssen Pharmaceuticals, Inc., Akron Biotech, and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Select Competitors (Total 80 Featured):
- Bayer AG
- Janssen Pharmaceuticals, Inc.
- Akron Biotech
- GeneCopoeia, Inc.
- Aldevron
- GenScript Biotech Corporation
- DNA TwoPointO Inc. (dba ATUM)
- Genelux Corporation
- Cell and Gene Therapy Catapult
- ID Pharma Co., Ltd.
- Global Life Sciences Solutions USA LLC (Cytiva)
- Algenex
- BioFactura
- Delphi Genetics
- FinVector OY
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISCANADAITALYREST OF EUROPEREST OF WORLDIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
Companies Mentioned
- Bayer AG
- Janssen Pharmaceuticals, Inc.
- Akron Biotech
- GeneCopoeia, Inc.
- Aldevron
- GenScript Biotech Corporation
- DNA TwoPointO Inc. (dba ATUM)
- Genelux Corporation
- Cell and Gene Therapy Catapult
- ID Pharma Co., Ltd.
- Global Life Sciences Solutions USA LLC (Cytiva)
- Algenex
- BioFactura
- Delphi Genetics
- FinVector OY
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 402 |
| Published | December 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 807.1 Million |
| Forecasted Market Value ( USD | $ 2600 Million |
| Compound Annual Growth Rate | 18.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
